News & Updates

Show Multimedia Only

Apathy mediates treatment efficacy against cancer-related fatigue

04 Sep 2020

Patient apathy appears to be an important factor in determining the efficacy of interventions targeting cancer-related fatigue (CRF), reports a new study.

Apathy mediates treatment efficacy against cancer-related fatigue

04 Sep 2020

Atezolizumab-bevacizumab may change the treatment landscape of liver cancer

04 Sep 2020 by

Safety data from the phase III IMbrave150 trial reinforce the previously reported favourable safety profile of atezolizumab-bevacizumab compared with sorafenib for unresectable hepatocellular carcinoma (HCC).

Atezolizumab-bevacizumab may change the treatment landscape of liver cancer

04 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Apathy mediates treatment efficacy against cancer-related fatigue

Apathy mediates treatment efficacy against cancer-related fatigue

Atezolizumab-bevacizumab may change the treatment landscape of liver cancer

Atezolizumab-bevacizumab may change the treatment landscape of liver cancer